Iqvia Holdings Inc. logo

Iqvia Holdings Inc. (0JDM)

Market Closed
25 Apr, 15:30
$
149. 08
-0.9
-0.6%
$
- Market Cap
38.04 P/E Ratio
0% Div Yield
67 Volume
10.19 Eps
$ 149.97
Previous Close
Day Range
147.03 149.08
Year Range
138.86 252.9

Summary

0JDM closed Friday lower at $149.08, a decrease of 0.6% from Thursday's close, completing a monthly decrease of -15.53% or $27.4. Over the past 12 months, 0JDM stock lost -25.3%.
0JDM is not paying dividends to its shareholders.
The last earnings report, released on Yesterday at 12:00 AM, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track 0JDM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

0JDM Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?

IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?

Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.

Zacks | 3 hours ago
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 3 hours ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 days ago

Iqvia Holdings Inc. Dividends

0JDM is not paying dividends to its shareholders.

Iqvia Holdings Inc. Earnings

30 Apr 2025 Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
3.11
Cons. EPS
3.12
EPS
31 Oct 2024 Date
2.81
Cons. EPS
2.84
EPS
30 Oct 2024 Date
2.81
Cons. EPS
-
EPS
30 Jul 2024 Date
2.57
Cons. EPS
-
EPS
0JDM is not paying dividends to its shareholders.
30 Apr 2025 Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
3.11
Cons. EPS
3.12
EPS
31 Oct 2024 Date
2.81
Cons. EPS
2.84
EPS
30 Oct 2024 Date
2.81
Cons. EPS
-
EPS
30 Jul 2024 Date
2.57
Cons. EPS
-
EPS

Iqvia Holdings Inc. (0JDM) FAQ

What is the stock price today?

The current price is $149.08.

On which exchange is it traded?

Iqvia Holdings Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0JDM.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Iqvia Holdings Inc. ever had a stock split?

No, there has never been a stock split.

Iqvia Holdings Inc. Profile

Diagnostics & Research Industry
Healthcare Sector
Mr. Ari Bousbib CEO
LSE Exchange
US46266C1053 ISIN
US Country
87,000 Employees
- Last Dividend
- Last Split
9 May 2013 IPO Date

Overview

IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.

Products and Services

  • Technology & Analytics Solutions
  • This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.

  • Research & Development Solutions
  • This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.

  • Contract Sales & Medical Solutions
  • Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.

Contact Information

Address: 2400 Ellis Road, Durham, NC, United States, 27703
Phone: 919 998 2000